Affy Expands GeneChip Deal with GlaxoSmithKline | GenomeWeb

NEW YORK, Sept 10 – Affymetrix said Monday that it had expanded its agreement to provide GlaxoSmithKline with its GeneChip technology. 

Under the terms of the deal, Glaxo’s research centers will be able to receive customized GeneChip arrays in smaller format sizes, providing them with lower cost arrays for high-throughput studies.

The deal reflects a new Affymetrix effort to offer specialized arrays at reduced prices.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.